nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—UGT1A9—Mycophenolic acid—psoriasis	0.0863	0.119	CbGbCtD
Buprenorphine—UGT1A9—Mycophenolate mofetil—psoriasis	0.0482	0.0666	CbGbCtD
Buprenorphine—CYP2A6—Methoxsalen—psoriasis	0.0408	0.0564	CbGbCtD
Buprenorphine—CYP2C8—Tazarotene—psoriasis	0.0312	0.0431	CbGbCtD
Buprenorphine—CYP3A5—Beclomethasone—psoriasis	0.0302	0.0417	CbGbCtD
Buprenorphine—CYP1A2—Clobetasol propionate—psoriasis	0.0297	0.041	CbGbCtD
Buprenorphine—ABCG2—Mycophenolate mofetil—psoriasis	0.0217	0.03	CbGbCtD
Buprenorphine—CYP2A6—Prednisolone—psoriasis	0.0198	0.0274	CbGbCtD
Buprenorphine—ABCG2—Hydrocortisone—psoriasis	0.0174	0.024	CbGbCtD
Buprenorphine—ABCG2—Cyclosporine—psoriasis	0.0164	0.0227	CbGbCtD
Buprenorphine—CYP1A2—Methoxsalen—psoriasis	0.0156	0.0215	CbGbCtD
Buprenorphine—CYP2D6—Hydroxyurea—psoriasis	0.014	0.0194	CbGbCtD
Buprenorphine—CYP2C8—Cholecalciferol—psoriasis	0.0133	0.0184	CbGbCtD
Buprenorphine—CYP3A7—Hydrocortisone—psoriasis	0.0129	0.0178	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0129	0.0178	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0121	0.0168	CbGbCtD
Buprenorphine—CYP3A7—Cyclosporine—psoriasis	0.0121	0.0168	CbGbCtD
Buprenorphine—CYP3A5—Mycophenolate mofetil—psoriasis	0.012	0.0166	CbGbCtD
Buprenorphine—CYP2A6—Dexamethasone—psoriasis	0.0117	0.0162	CbGbCtD
Buprenorphine—CYP2C8—Mycophenolate mofetil—psoriasis	0.0116	0.016	CbGbCtD
Buprenorphine—CYP2C19—Cholecalciferol—psoriasis	0.0112	0.0154	CbGbCtD
Buprenorphine—ABCG2—Dexamethasone—psoriasis	0.0108	0.015	CbGbCtD
Buprenorphine—CYP3A4—Calcitriol—psoriasis	0.0105	0.0145	CbGbCtD
Buprenorphine—CYP3A5—Hydrocortisone—psoriasis	0.00965	0.0133	CbGbCtD
Buprenorphine—CYP2C9—Cholecalciferol—psoriasis	0.0093	0.0128	CbGbCtD
Buprenorphine—CYP2C8—Hydrocortisone—psoriasis	0.00927	0.0128	CbGbCtD
Buprenorphine—CYP3A5—Cyclosporine—psoriasis	0.00911	0.0126	CbGbCtD
Buprenorphine—CYP2C8—Cyclosporine—psoriasis	0.00876	0.0121	CbGbCtD
Buprenorphine—ABCG2—Methotrexate—psoriasis	0.0087	0.012	CbGbCtD
Buprenorphine—CYP2D6—Cholecalciferol—psoriasis	0.0085	0.0117	CbGbCtD
Buprenorphine—CYP3A4—Methoxsalen—psoriasis	0.00816	0.0113	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.008	0.011	CbGbCtD
Buprenorphine—CYP3A7—Dexamethasone—psoriasis	0.008	0.011	CbGbCtD
Buprenorphine—ABCB1—Mycophenolate mofetil—psoriasis	0.00782	0.0108	CbGbCtD
Buprenorphine—CYP2C19—Prednisone—psoriasis	0.00775	0.0107	CbGbCtD
Buprenorphine—CYP2C19—Cyclosporine—psoriasis	0.00735	0.0101	CbGbCtD
Buprenorphine—ABCB1—Betamethasone—psoriasis	0.00671	0.00927	CbGbCtD
Buprenorphine—ABCB1—Prednisolone—psoriasis	0.00662	0.00915	CbGbCtD
Buprenorphine—ABCB1—Hydrocortisone—psoriasis	0.00628	0.00867	CbGbCtD
Buprenorphine—ABCB1—Prednisone—psoriasis	0.00625	0.00864	CbGbCtD
Buprenorphine—CYP2C9—Cyclosporine—psoriasis	0.00611	0.00844	CbGbCtD
Buprenorphine—CYP3A5—Dexamethasone—psoriasis	0.006	0.00829	CbGbCtD
Buprenorphine—ABCB1—Cyclosporine—psoriasis	0.00593	0.00819	CbGbCtD
Buprenorphine—CYP2C8—Dexamethasone—psoriasis	0.00577	0.00797	CbGbCtD
Buprenorphine—CYP2D6—Cyclosporine—psoriasis	0.00559	0.00772	CbGbCtD
Buprenorphine—CYP3A4—Cholecalciferol—psoriasis	0.00541	0.00747	CbGbCtD
Buprenorphine—CYP2C19—Dexamethasone—psoriasis	0.00484	0.00668	CbGbCtD
Buprenorphine—CYP3A4—Mycophenolate mofetil—psoriasis	0.00469	0.00647	CbGbCtD
Buprenorphine—CYP3A4—Triamcinolone—psoriasis	0.00469	0.00647	CbGbCtD
Buprenorphine—CYP2C9—Dexamethasone—psoriasis	0.00402	0.00556	CbGbCtD
Buprenorphine—CYP3A4—Betamethasone—psoriasis	0.00402	0.00555	CbGbCtD
Buprenorphine—CYP3A4—Prednisolone—psoriasis	0.00397	0.00548	CbGbCtD
Buprenorphine—ABCB1—Dexamethasone—psoriasis	0.0039	0.00539	CbGbCtD
Buprenorphine—CYP3A4—Hydrocortisone—psoriasis	0.00376	0.0052	CbGbCtD
Buprenorphine—CYP3A4—Prednisone—psoriasis	0.00375	0.00518	CbGbCtD
Buprenorphine—CYP2D6—Dexamethasone—psoriasis	0.00368	0.00508	CbGbCtD
Buprenorphine—CYP3A4—Cyclosporine—psoriasis	0.00355	0.00491	CbGbCtD
Buprenorphine—ABCB1—Methotrexate—psoriasis	0.00314	0.00433	CbGbCtD
Buprenorphine—CYP3A4—Dexamethasone—psoriasis	0.00234	0.00323	CbGbCtD
Buprenorphine—ABCB1—Allograft Rejection—IL12B—psoriasis	9.86e-05	0.00169	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—HLA-E—psoriasis	9.62e-05	0.00165	CbGpPWpGaD
Buprenorphine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.47e-05	0.00162	CbGpPWpGaD
Buprenorphine—CYP1A2—Tryptophan metabolism—CAT—psoriasis	9.39e-05	0.00161	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—CCL20—psoriasis	9.32e-05	0.0016	CbGpPWpGaD
Buprenorphine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	9.22e-05	0.00158	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—HCAR2—psoriasis	9.21e-05	0.00158	CbGpPWpGaD
Buprenorphine—ABCG2—Fluoropyrimidine Activity—TP53—psoriasis	8.99e-05	0.00154	CbGpPWpGaD
Buprenorphine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.96e-05	0.00154	CbGpPWpGaD
Buprenorphine—OPRL1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	8.83e-05	0.00151	CbGpPWpGaD
Buprenorphine—UGT1A9—PPARA activates gene expression—PPARG—psoriasis	8.64e-05	0.00148	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—HCAR2—psoriasis	8.57e-05	0.00147	CbGpPWpGaD
Buprenorphine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	8.46e-05	0.00145	CbGpPWpGaD
Buprenorphine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	8.4e-05	0.00144	CbGpPWpGaD
Buprenorphine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	8.29e-05	0.00142	CbGpPWpGaD
Buprenorphine—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	8.17e-05	0.0014	CbGpPWpGaD
Buprenorphine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.1e-05	0.00139	CbGpPWpGaD
Buprenorphine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	8.06e-05	0.00138	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	7.96e-05	0.00137	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—CCL20—psoriasis	7.88e-05	0.00135	CbGpPWpGaD
Buprenorphine—OPRM1—TCR Signaling Pathway—CD4—psoriasis	7.86e-05	0.00135	CbGpPWpGaD
Buprenorphine—ABCG2—HIF-1-alpha transcription factor network—JUN—psoriasis	7.83e-05	0.00134	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—HCAR2—psoriasis	7.78e-05	0.00133	CbGpPWpGaD
Buprenorphine—OPRL1—Circadian rythm related genes—TP53—psoriasis	7.72e-05	0.00132	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—NDUFA5—psoriasis	7.56e-05	0.0013	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CCL20—psoriasis	7.55e-05	0.00129	CbGpPWpGaD
Buprenorphine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	7.41e-05	0.00127	CbGpPWpGaD
Buprenorphine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	7.25e-05	0.00124	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—IL10—psoriasis	7.21e-05	0.00124	CbGpPWpGaD
Buprenorphine—OPRL1—Circadian rythm related genes—IL6—psoriasis	7.07e-05	0.00121	CbGpPWpGaD
Buprenorphine—OPRM1—TCR Signaling Pathway—JUN—psoriasis	7.04e-05	0.00121	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—IL4—psoriasis	7.01e-05	0.0012	CbGpPWpGaD
Buprenorphine—Body temperature increased—Cyclosporine—psoriasis	6.9e-05	0.000317	CcSEcCtD
Buprenorphine—Abdominal pain—Cyclosporine—psoriasis	6.9e-05	0.000317	CcSEcCtD
Buprenorphine—Anxiety—Betamethasone—psoriasis	6.89e-05	0.000316	CcSEcCtD
Buprenorphine—Anxiety—Dexamethasone—psoriasis	6.89e-05	0.000316	CcSEcCtD
Buprenorphine—Vomiting—Mycophenolic acid—psoriasis	6.86e-05	0.000315	CcSEcCtD
Buprenorphine—ABCB1—Allograft Rejection—HLA-B—psoriasis	6.86e-05	0.00118	CbGpPWpGaD
Buprenorphine—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	6.85e-05	0.00117	CbGpPWpGaD
Buprenorphine—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	6.84e-05	0.00117	CbGpPWpGaD
Buprenorphine—Discomfort—Dexamethasone—psoriasis	6.83e-05	0.000314	CcSEcCtD
Buprenorphine—Discomfort—Betamethasone—psoriasis	6.83e-05	0.000314	CcSEcCtD
Buprenorphine—Dyspepsia—Hydrocortisone—psoriasis	6.83e-05	0.000314	CcSEcCtD
Buprenorphine—Rash—Mycophenolic acid—psoriasis	6.8e-05	0.000312	CcSEcCtD
Buprenorphine—Dermatitis—Mycophenolic acid—psoriasis	6.79e-05	0.000312	CcSEcCtD
Buprenorphine—Pain—Prednisolone—psoriasis	6.79e-05	0.000312	CcSEcCtD
Buprenorphine—OPRM1—TCR Signaling Pathway—NFKB1—psoriasis	6.77e-05	0.00116	CbGpPWpGaD
Buprenorphine—Urticaria—Mycophenolate mofetil—psoriasis	6.76e-05	0.000311	CcSEcCtD
Buprenorphine—Headache—Mycophenolic acid—psoriasis	6.76e-05	0.00031	CcSEcCtD
Buprenorphine—Decreased appetite—Hydrocortisone—psoriasis	6.74e-05	0.00031	CcSEcCtD
Buprenorphine—Pharyngitis—Methotrexate—psoriasis	6.74e-05	0.000309	CcSEcCtD
Buprenorphine—Body temperature increased—Mycophenolate mofetil—psoriasis	6.73e-05	0.000309	CcSEcCtD
Buprenorphine—Abdominal pain—Mycophenolate mofetil—psoriasis	6.73e-05	0.000309	CcSEcCtD
Buprenorphine—OPRL1—GPCR ligand binding—CXCL8—psoriasis	6.72e-05	0.00115	CbGpPWpGaD
Buprenorphine—Urinary tract disorder—Methotrexate—psoriasis	6.7e-05	0.000308	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Hydrocortisone—psoriasis	6.69e-05	0.000308	CcSEcCtD
Buprenorphine—Fatigue—Hydrocortisone—psoriasis	6.69e-05	0.000307	CcSEcCtD
Buprenorphine—Vision blurred—Prednisone—psoriasis	6.66e-05	0.000306	CcSEcCtD
Buprenorphine—Urethral disorder—Methotrexate—psoriasis	6.65e-05	0.000306	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Triamcinolone—psoriasis	6.65e-05	0.000306	CcSEcCtD
Buprenorphine—Pain—Hydrocortisone—psoriasis	6.63e-05	0.000305	CcSEcCtD
Buprenorphine—Oedema—Betamethasone—psoriasis	6.63e-05	0.000304	CcSEcCtD
Buprenorphine—Anaphylactic shock—Dexamethasone—psoriasis	6.63e-05	0.000304	CcSEcCtD
Buprenorphine—Oedema—Dexamethasone—psoriasis	6.63e-05	0.000304	CcSEcCtD
Buprenorphine—Anaphylactic shock—Betamethasone—psoriasis	6.63e-05	0.000304	CcSEcCtD
Buprenorphine—Insomnia—Triamcinolone—psoriasis	6.6e-05	0.000303	CcSEcCtD
Buprenorphine—Infection—Betamethasone—psoriasis	6.58e-05	0.000302	CcSEcCtD
Buprenorphine—Infection—Dexamethasone—psoriasis	6.58e-05	0.000302	CcSEcCtD
Buprenorphine—Ill-defined disorder—Prednisone—psoriasis	6.56e-05	0.000301	CcSEcCtD
Buprenorphine—Paraesthesia—Triamcinolone—psoriasis	6.56e-05	0.000301	CcSEcCtD
Buprenorphine—Feeling abnormal—Prednisolone—psoriasis	6.54e-05	0.000301	CcSEcCtD
Buprenorphine—Visual impairment—Methotrexate—psoriasis	6.54e-05	0.0003	CcSEcCtD
Buprenorphine—Shock—Dexamethasone—psoriasis	6.52e-05	0.000299	CcSEcCtD
Buprenorphine—Shock—Betamethasone—psoriasis	6.52e-05	0.000299	CcSEcCtD
Buprenorphine—Dyspnoea—Triamcinolone—psoriasis	6.51e-05	0.000299	CcSEcCtD
Buprenorphine—Nervous system disorder—Dexamethasone—psoriasis	6.5e-05	0.000298	CcSEcCtD
Buprenorphine—Nervous system disorder—Betamethasone—psoriasis	6.5e-05	0.000298	CcSEcCtD
Buprenorphine—Agitation—Prednisone—psoriasis	6.5e-05	0.000298	CcSEcCtD
Buprenorphine—Tachycardia—Dexamethasone—psoriasis	6.47e-05	0.000297	CcSEcCtD
Buprenorphine—Tachycardia—Betamethasone—psoriasis	6.47e-05	0.000297	CcSEcCtD
Buprenorphine—Angioedema—Prednisone—psoriasis	6.46e-05	0.000297	CcSEcCtD
Buprenorphine—CYP2C18—Metabolism—CYP2S1—psoriasis	6.43e-05	0.0011	CbGpPWpGaD
Buprenorphine—Hypersensitivity—Cyclosporine—psoriasis	6.43e-05	0.000295	CcSEcCtD
Buprenorphine—Dyspepsia—Triamcinolone—psoriasis	6.43e-05	0.000295	CcSEcCtD
Buprenorphine—Nausea—Mycophenolic acid—psoriasis	6.41e-05	0.000294	CcSEcCtD
Buprenorphine—Hyperhidrosis—Dexamethasone—psoriasis	6.4e-05	0.000294	CcSEcCtD
Buprenorphine—Hyperhidrosis—Betamethasone—psoriasis	6.4e-05	0.000294	CcSEcCtD
Buprenorphine—Feeling abnormal—Hydrocortisone—psoriasis	6.39e-05	0.000294	CcSEcCtD
Buprenorphine—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	6.38e-05	0.00109	CbGpPWpGaD
Buprenorphine—Malaise—Prednisone—psoriasis	6.38e-05	0.000293	CcSEcCtD
Buprenorphine—ABCB1—Allograft Rejection—HLA-A—psoriasis	6.35e-05	0.00109	CbGpPWpGaD
Buprenorphine—Vertigo—Prednisone—psoriasis	6.35e-05	0.000292	CcSEcCtD
Buprenorphine—Eye disorder—Methotrexate—psoriasis	6.34e-05	0.000291	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Hydrocortisone—psoriasis	6.34e-05	0.000291	CcSEcCtD
Buprenorphine—Syncope—Prednisone—psoriasis	6.34e-05	0.000291	CcSEcCtD
Buprenorphine—Tinnitus—Methotrexate—psoriasis	6.33e-05	0.000291	CcSEcCtD
Buprenorphine—Anorexia—Betamethasone—psoriasis	6.32e-05	0.00029	CcSEcCtD
Buprenorphine—Anorexia—Dexamethasone—psoriasis	6.32e-05	0.00029	CcSEcCtD
Buprenorphine—Urticaria—Prednisolone—psoriasis	6.31e-05	0.00029	CcSEcCtD
Buprenorphine—Cardiac disorder—Methotrexate—psoriasis	6.3e-05	0.000289	CcSEcCtD
Buprenorphine—Fatigue—Triamcinolone—psoriasis	6.3e-05	0.000289	CcSEcCtD
Buprenorphine—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	6.28e-05	0.00108	CbGpPWpGaD
Buprenorphine—Hypersensitivity—Mycophenolate mofetil—psoriasis	6.27e-05	0.000288	CcSEcCtD
Buprenorphine—Asthenia—Cyclosporine—psoriasis	6.26e-05	0.000288	CcSEcCtD
Buprenorphine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.25e-05	0.00107	CbGpPWpGaD
Buprenorphine—Pain—Triamcinolone—psoriasis	6.24e-05	0.000287	CcSEcCtD
Buprenorphine—Loss of consciousness—Prednisone—psoriasis	6.21e-05	0.000285	CcSEcCtD
Buprenorphine—OPRD1—Signaling Pathways—HCAR2—psoriasis	6.2e-05	0.00106	CbGpPWpGaD
Buprenorphine—Hypotension—Betamethasone—psoriasis	6.19e-05	0.000284	CcSEcCtD
Buprenorphine—Hypotension—Dexamethasone—psoriasis	6.19e-05	0.000284	CcSEcCtD
Buprenorphine—Pruritus—Cyclosporine—psoriasis	6.17e-05	0.000284	CcSEcCtD
Buprenorphine—Urticaria—Hydrocortisone—psoriasis	6.16e-05	0.000283	CcSEcCtD
Buprenorphine—Angiopathy—Methotrexate—psoriasis	6.16e-05	0.000283	CcSEcCtD
Buprenorphine—Immune system disorder—Methotrexate—psoriasis	6.13e-05	0.000282	CcSEcCtD
Buprenorphine—Abdominal pain—Hydrocortisone—psoriasis	6.13e-05	0.000282	CcSEcCtD
Buprenorphine—Body temperature increased—Hydrocortisone—psoriasis	6.13e-05	0.000282	CcSEcCtD
Buprenorphine—Convulsion—Prednisone—psoriasis	6.13e-05	0.000281	CcSEcCtD
Buprenorphine—Mediastinal disorder—Methotrexate—psoriasis	6.12e-05	0.000281	CcSEcCtD
Buprenorphine—Asthenia—Mycophenolate mofetil—psoriasis	6.11e-05	0.000281	CcSEcCtD
Buprenorphine—Hypertension—Prednisone—psoriasis	6.1e-05	0.00028	CcSEcCtD
Buprenorphine—Chills—Methotrexate—psoriasis	6.09e-05	0.00028	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Betamethasone—psoriasis	6.04e-05	0.000277	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Dexamethasone—psoriasis	6.04e-05	0.000277	CcSEcCtD
Buprenorphine—Pruritus—Mycophenolate mofetil—psoriasis	6.02e-05	0.000277	CcSEcCtD
Buprenorphine—Arthralgia—Prednisone—psoriasis	6.02e-05	0.000276	CcSEcCtD
Buprenorphine—Myalgia—Prednisone—psoriasis	6.02e-05	0.000276	CcSEcCtD
Buprenorphine—Feeling abnormal—Triamcinolone—psoriasis	6.02e-05	0.000276	CcSEcCtD
Buprenorphine—OPRD1—GPCR downstream signaling—CCL20—psoriasis	6.01e-05	0.00103	CbGpPWpGaD
Buprenorphine—Anxiety—Prednisone—psoriasis	6e-05	0.000276	CcSEcCtD
Buprenorphine—Insomnia—Betamethasone—psoriasis	5.99e-05	0.000275	CcSEcCtD
Buprenorphine—Insomnia—Dexamethasone—psoriasis	5.99e-05	0.000275	CcSEcCtD
Buprenorphine—UGT1A9—Metabolism—NDUFA5—psoriasis	5.98e-05	0.00103	CbGpPWpGaD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	5.98e-05	0.000275	CcSEcCtD
Buprenorphine—Diarrhoea—Cyclosporine—psoriasis	5.97e-05	0.000274	CcSEcCtD
Buprenorphine—Paraesthesia—Dexamethasone—psoriasis	5.95e-05	0.000273	CcSEcCtD
Buprenorphine—Paraesthesia—Betamethasone—psoriasis	5.95e-05	0.000273	CcSEcCtD
Buprenorphine—Discomfort—Prednisone—psoriasis	5.95e-05	0.000273	CcSEcCtD
Buprenorphine—Mental disorder—Methotrexate—psoriasis	5.95e-05	0.000273	CcSEcCtD
Buprenorphine—Malnutrition—Methotrexate—psoriasis	5.91e-05	0.000271	CcSEcCtD
Buprenorphine—Erythema—Methotrexate—psoriasis	5.91e-05	0.000271	CcSEcCtD
Buprenorphine—Hypersensitivity—Prednisolone—psoriasis	5.85e-05	0.000269	CcSEcCtD
Buprenorphine—Dyspepsia—Dexamethasone—psoriasis	5.83e-05	0.000268	CcSEcCtD
Buprenorphine—Dyspepsia—Betamethasone—psoriasis	5.83e-05	0.000268	CcSEcCtD
Buprenorphine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	5.83e-05	0.000999	CbGpPWpGaD
Buprenorphine—Diarrhoea—Mycophenolate mofetil—psoriasis	5.82e-05	0.000268	CcSEcCtD
Buprenorphine—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	5.8e-05	0.000995	CbGpPWpGaD
Buprenorphine—Urticaria—Triamcinolone—psoriasis	5.8e-05	0.000266	CcSEcCtD
Buprenorphine—Dysgeusia—Methotrexate—psoriasis	5.79e-05	0.000266	CcSEcCtD
Buprenorphine—Body temperature increased—Triamcinolone—psoriasis	5.77e-05	0.000265	CcSEcCtD
Buprenorphine—Dizziness—Cyclosporine—psoriasis	5.77e-05	0.000265	CcSEcCtD
Buprenorphine—Oedema—Prednisone—psoriasis	5.77e-05	0.000265	CcSEcCtD
Buprenorphine—Anaphylactic shock—Prednisone—psoriasis	5.77e-05	0.000265	CcSEcCtD
Buprenorphine—Decreased appetite—Betamethasone—psoriasis	5.76e-05	0.000265	CcSEcCtD
Buprenorphine—Decreased appetite—Dexamethasone—psoriasis	5.76e-05	0.000265	CcSEcCtD
Buprenorphine—Infection—Prednisone—psoriasis	5.73e-05	0.000263	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Betamethasone—psoriasis	5.72e-05	0.000263	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Dexamethasone—psoriasis	5.72e-05	0.000263	CcSEcCtD
Buprenorphine—Back pain—Methotrexate—psoriasis	5.71e-05	0.000263	CcSEcCtD
Buprenorphine—Hypersensitivity—Hydrocortisone—psoriasis	5.71e-05	0.000262	CcSEcCtD
Buprenorphine—Fatigue—Dexamethasone—psoriasis	5.71e-05	0.000262	CcSEcCtD
Buprenorphine—Fatigue—Betamethasone—psoriasis	5.71e-05	0.000262	CcSEcCtD
Buprenorphine—Shock—Prednisone—psoriasis	5.68e-05	0.000261	CcSEcCtD
Buprenorphine—Pain—Betamethasone—psoriasis	5.67e-05	0.00026	CcSEcCtD
Buprenorphine—Pain—Dexamethasone—psoriasis	5.67e-05	0.00026	CcSEcCtD
Buprenorphine—Nervous system disorder—Prednisone—psoriasis	5.66e-05	0.00026	CcSEcCtD
Buprenorphine—Tachycardia—Prednisone—psoriasis	5.63e-05	0.000259	CcSEcCtD
Buprenorphine—Dizziness—Mycophenolate mofetil—psoriasis	5.63e-05	0.000259	CcSEcCtD
Buprenorphine—OPRD1—Peptide ligand-binding receptors—CXCL8—psoriasis	5.62e-05	0.000963	CbGpPWpGaD
Buprenorphine—Skin disorder—Prednisone—psoriasis	5.6e-05	0.000257	CcSEcCtD
Buprenorphine—Hyperhidrosis—Prednisone—psoriasis	5.58e-05	0.000256	CcSEcCtD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.57e-05	0.000956	CbGpPWpGaD
Buprenorphine—Vision blurred—Methotrexate—psoriasis	5.57e-05	0.000256	CcSEcCtD
Buprenorphine—Asthenia—Hydrocortisone—psoriasis	5.56e-05	0.000256	CcSEcCtD
Buprenorphine—Vomiting—Cyclosporine—psoriasis	5.55e-05	0.000255	CcSEcCtD
Buprenorphine—Rash—Cyclosporine—psoriasis	5.5e-05	0.000253	CcSEcCtD
Buprenorphine—Anorexia—Prednisone—psoriasis	5.5e-05	0.000253	CcSEcCtD
Buprenorphine—Dermatitis—Cyclosporine—psoriasis	5.5e-05	0.000252	CcSEcCtD
Buprenorphine—Pruritus—Hydrocortisone—psoriasis	5.49e-05	0.000252	CcSEcCtD
Buprenorphine—Ill-defined disorder—Methotrexate—psoriasis	5.48e-05	0.000252	CcSEcCtD
Buprenorphine—Headache—Cyclosporine—psoriasis	5.47e-05	0.000251	CcSEcCtD
Buprenorphine—Feeling abnormal—Betamethasone—psoriasis	5.46e-05	0.000251	CcSEcCtD
Buprenorphine—Feeling abnormal—Dexamethasone—psoriasis	5.46e-05	0.000251	CcSEcCtD
Buprenorphine—OPRD1—Signaling by GPCR—CCL20—psoriasis	5.45e-05	0.000935	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—HCAR2—psoriasis	5.44e-05	0.000932	CbGpPWpGaD
Buprenorphine—Gastrointestinal pain—Betamethasone—psoriasis	5.42e-05	0.000249	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Dexamethasone—psoriasis	5.42e-05	0.000249	CcSEcCtD
Buprenorphine—Vomiting—Mycophenolate mofetil—psoriasis	5.41e-05	0.000249	CcSEcCtD
Buprenorphine—Hypersensitivity—Triamcinolone—psoriasis	5.38e-05	0.000247	CcSEcCtD
Buprenorphine—OPRD1—Signaling Pathways—TAGAP—psoriasis	5.38e-05	0.000922	CbGpPWpGaD
Buprenorphine—Rash—Mycophenolate mofetil—psoriasis	5.37e-05	0.000247	CcSEcCtD
Buprenorphine—Dermatitis—Mycophenolate mofetil—psoriasis	5.36e-05	0.000246	CcSEcCtD
Buprenorphine—Headache—Mycophenolate mofetil—psoriasis	5.33e-05	0.000245	CcSEcCtD
Buprenorphine—Malaise—Methotrexate—psoriasis	5.33e-05	0.000245	CcSEcCtD
Buprenorphine—Vertigo—Methotrexate—psoriasis	5.31e-05	0.000244	CcSEcCtD
Buprenorphine—Diarrhoea—Hydrocortisone—psoriasis	5.31e-05	0.000244	CcSEcCtD
Buprenorphine—OPRK1—GPCR downstream signaling—CCL20—psoriasis	5.27e-05	0.000903	CbGpPWpGaD
Buprenorphine—Urticaria—Betamethasone—psoriasis	5.26e-05	0.000242	CcSEcCtD
Buprenorphine—Urticaria—Dexamethasone—psoriasis	5.26e-05	0.000242	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Prednisone—psoriasis	5.26e-05	0.000241	CcSEcCtD
Buprenorphine—Dizziness—Prednisolone—psoriasis	5.25e-05	0.000241	CcSEcCtD
Buprenorphine—Asthenia—Triamcinolone—psoriasis	5.24e-05	0.000241	CcSEcCtD
Buprenorphine—Abdominal pain—Betamethasone—psoriasis	5.24e-05	0.000241	CcSEcCtD
Buprenorphine—Body temperature increased—Dexamethasone—psoriasis	5.24e-05	0.000241	CcSEcCtD
Buprenorphine—Body temperature increased—Betamethasone—psoriasis	5.24e-05	0.000241	CcSEcCtD
Buprenorphine—Abdominal pain—Dexamethasone—psoriasis	5.24e-05	0.000241	CcSEcCtD
Buprenorphine—Insomnia—Prednisone—psoriasis	5.22e-05	0.00024	CcSEcCtD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	5.22e-05	0.000894	CbGpPWpGaD
Buprenorphine—Nausea—Cyclosporine—psoriasis	5.18e-05	0.000238	CcSEcCtD
Buprenorphine—Paraesthesia—Prednisone—psoriasis	5.18e-05	0.000238	CcSEcCtD
Buprenorphine—Pruritus—Triamcinolone—psoriasis	5.17e-05	0.000237	CcSEcCtD
Buprenorphine—Cough—Methotrexate—psoriasis	5.16e-05	0.000237	CcSEcCtD
Buprenorphine—Dizziness—Hydrocortisone—psoriasis	5.13e-05	0.000236	CcSEcCtD
Buprenorphine—Convulsion—Methotrexate—psoriasis	5.12e-05	0.000235	CcSEcCtD
Buprenorphine—UGT1A9—Metabolism—CYP2S1—psoriasis	5.08e-05	0.000872	CbGpPWpGaD
Buprenorphine—Dyspepsia—Prednisone—psoriasis	5.08e-05	0.000233	CcSEcCtD
Buprenorphine—ABCG2—Metabolism—NDUFA5—psoriasis	5.07e-05	0.00087	CbGpPWpGaD
Buprenorphine—Nausea—Mycophenolate mofetil—psoriasis	5.06e-05	0.000232	CcSEcCtD
Buprenorphine—Chest pain—Methotrexate—psoriasis	5.03e-05	0.000231	CcSEcCtD
Buprenorphine—Myalgia—Methotrexate—psoriasis	5.03e-05	0.000231	CcSEcCtD
Buprenorphine—Arthralgia—Methotrexate—psoriasis	5.03e-05	0.000231	CcSEcCtD
Buprenorphine—CYP3A7—Metabolism—NDUFA5—psoriasis	5.03e-05	0.000862	CbGpPWpGaD
Buprenorphine—Decreased appetite—Prednisone—psoriasis	5.02e-05	0.00023	CcSEcCtD
Buprenorphine—Rash—Prednisolone—psoriasis	5.01e-05	0.00023	CcSEcCtD
Buprenorphine—Dermatitis—Prednisolone—psoriasis	5e-05	0.00023	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	5e-05	0.000229	CcSEcCtD
Buprenorphine—Fatigue—Prednisone—psoriasis	4.97e-05	0.000229	CcSEcCtD
Buprenorphine—Headache—Prednisolone—psoriasis	4.97e-05	0.000228	CcSEcCtD
Buprenorphine—Discomfort—Methotrexate—psoriasis	4.97e-05	0.000228	CcSEcCtD
Buprenorphine—Constipation—Prednisone—psoriasis	4.93e-05	0.000227	CcSEcCtD
Buprenorphine—Vomiting—Hydrocortisone—psoriasis	4.93e-05	0.000226	CcSEcCtD
Buprenorphine—OPRK1—Peptide ligand-binding receptors—CXCL8—psoriasis	4.93e-05	0.000845	CbGpPWpGaD
Buprenorphine—Rash—Hydrocortisone—psoriasis	4.89e-05	0.000225	CcSEcCtD
Buprenorphine—Dermatitis—Hydrocortisone—psoriasis	4.88e-05	0.000224	CcSEcCtD
Buprenorphine—Confusional state—Methotrexate—psoriasis	4.86e-05	0.000223	CcSEcCtD
Buprenorphine—Headache—Hydrocortisone—psoriasis	4.86e-05	0.000223	CcSEcCtD
Buprenorphine—Dizziness—Triamcinolone—psoriasis	4.83e-05	0.000222	CcSEcCtD
Buprenorphine—Anaphylactic shock—Methotrexate—psoriasis	4.82e-05	0.000222	CcSEcCtD
Buprenorphine—Infection—Methotrexate—psoriasis	4.79e-05	0.00022	CcSEcCtD
Buprenorphine—OPRK1—Signaling by GPCR—CCL20—psoriasis	4.78e-05	0.00082	CbGpPWpGaD
Buprenorphine—Feeling abnormal—Prednisone—psoriasis	4.75e-05	0.000218	CcSEcCtD
Buprenorphine—Asthenia—Dexamethasone—psoriasis	4.75e-05	0.000218	CcSEcCtD
Buprenorphine—Asthenia—Betamethasone—psoriasis	4.75e-05	0.000218	CcSEcCtD
Buprenorphine—OPRD1—G alpha (i) signalling events—CXCL8—psoriasis	4.74e-05	0.000813	CbGpPWpGaD
Buprenorphine—Nervous system disorder—Methotrexate—psoriasis	4.73e-05	0.000217	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Prednisone—psoriasis	4.72e-05	0.000217	CcSEcCtD
Buprenorphine—Nausea—Prednisolone—psoriasis	4.72e-05	0.000217	CcSEcCtD
Buprenorphine—OPRK1—Signaling Pathways—TAGAP—psoriasis	4.72e-05	0.000809	CbGpPWpGaD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	4.71e-05	0.000808	CbGpPWpGaD
Buprenorphine—Pruritus—Betamethasone—psoriasis	4.69e-05	0.000215	CcSEcCtD
Buprenorphine—Pruritus—Dexamethasone—psoriasis	4.69e-05	0.000215	CcSEcCtD
Buprenorphine—Skin disorder—Methotrexate—psoriasis	4.68e-05	0.000215	CcSEcCtD
Buprenorphine—Hyperhidrosis—Methotrexate—psoriasis	4.66e-05	0.000214	CcSEcCtD
Buprenorphine—Vomiting—Triamcinolone—psoriasis	4.64e-05	0.000213	CcSEcCtD
Buprenorphine—CYP2A6—Metabolism—NDUFA5—psoriasis	4.61e-05	0.00079	CbGpPWpGaD
Buprenorphine—Nausea—Hydrocortisone—psoriasis	4.61e-05	0.000212	CcSEcCtD
Buprenorphine—Rash—Triamcinolone—psoriasis	4.6e-05	0.000211	CcSEcCtD
Buprenorphine—Dermatitis—Triamcinolone—psoriasis	4.6e-05	0.000211	CcSEcCtD
Buprenorphine—OPRM1—Signaling Pathways—HCAR2—psoriasis	4.6e-05	0.000788	CbGpPWpGaD
Buprenorphine—Anorexia—Methotrexate—psoriasis	4.6e-05	0.000211	CcSEcCtD
Buprenorphine—Urticaria—Prednisone—psoriasis	4.58e-05	0.000211	CcSEcCtD
Buprenorphine—Headache—Triamcinolone—psoriasis	4.57e-05	0.00021	CcSEcCtD
Buprenorphine—Body temperature increased—Prednisone—psoriasis	4.56e-05	0.00021	CcSEcCtD
Buprenorphine—Abdominal pain—Prednisone—psoriasis	4.56e-05	0.00021	CcSEcCtD
Buprenorphine—Diarrhoea—Dexamethasone—psoriasis	4.53e-05	0.000208	CcSEcCtD
Buprenorphine—Diarrhoea—Betamethasone—psoriasis	4.53e-05	0.000208	CcSEcCtD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	4.51e-05	0.000773	CbGpPWpGaD
Buprenorphine—Hypotension—Methotrexate—psoriasis	4.51e-05	0.000207	CcSEcCtD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	4.5e-05	0.000771	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—CCL20—psoriasis	4.45e-05	0.000763	CbGpPWpGaD
Buprenorphine—Musculoskeletal discomfort—Methotrexate—psoriasis	4.39e-05	0.000202	CcSEcCtD
Buprenorphine—Dizziness—Betamethasone—psoriasis	4.38e-05	0.000201	CcSEcCtD
Buprenorphine—Dizziness—Dexamethasone—psoriasis	4.38e-05	0.000201	CcSEcCtD
Buprenorphine—Insomnia—Methotrexate—psoriasis	4.36e-05	0.0002	CcSEcCtD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	4.34e-05	0.000744	CbGpPWpGaD
Buprenorphine—Nausea—Triamcinolone—psoriasis	4.34e-05	0.000199	CcSEcCtD
Buprenorphine—Paraesthesia—Methotrexate—psoriasis	4.33e-05	0.000199	CcSEcCtD
Buprenorphine—ABCG2—Metabolism—CYP2S1—psoriasis	4.31e-05	0.00074	CbGpPWpGaD
Buprenorphine—Dyspnoea—Methotrexate—psoriasis	4.3e-05	0.000197	CcSEcCtD
Buprenorphine—Somnolence—Methotrexate—psoriasis	4.29e-05	0.000197	CcSEcCtD
Buprenorphine—CYP3A7—Metabolism—CYP2S1—psoriasis	4.28e-05	0.000733	CbGpPWpGaD
Buprenorphine—OPRM1—TCR Signaling Pathway—IL6—psoriasis	4.25e-05	0.000729	CbGpPWpGaD
Buprenorphine—Hypersensitivity—Prednisone—psoriasis	4.25e-05	0.000195	CcSEcCtD
Buprenorphine—Dyspepsia—Methotrexate—psoriasis	4.24e-05	0.000195	CcSEcCtD
Buprenorphine—ABCB1—Allograft Rejection—IFNG—psoriasis	4.24e-05	0.000727	CbGpPWpGaD
Buprenorphine—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	4.23e-05	0.000725	CbGpPWpGaD
Buprenorphine—Vomiting—Betamethasone—psoriasis	4.21e-05	0.000194	CcSEcCtD
Buprenorphine—Vomiting—Dexamethasone—psoriasis	4.21e-05	0.000194	CcSEcCtD
Buprenorphine—Decreased appetite—Methotrexate—psoriasis	4.19e-05	0.000193	CcSEcCtD
Buprenorphine—Rash—Betamethasone—psoriasis	4.18e-05	0.000192	CcSEcCtD
Buprenorphine—Rash—Dexamethasone—psoriasis	4.18e-05	0.000192	CcSEcCtD
Buprenorphine—Dermatitis—Betamethasone—psoriasis	4.17e-05	0.000192	CcSEcCtD
Buprenorphine—Dermatitis—Dexamethasone—psoriasis	4.17e-05	0.000192	CcSEcCtD
Buprenorphine—OPRM1—Peptide ligand-binding receptors—CXCL8—psoriasis	4.16e-05	0.000714	CbGpPWpGaD
Buprenorphine—Gastrointestinal disorder—Methotrexate—psoriasis	4.16e-05	0.000191	CcSEcCtD
Buprenorphine—Fatigue—Methotrexate—psoriasis	4.16e-05	0.000191	CcSEcCtD
Buprenorphine—OPRK1—G alpha (i) signalling events—CXCL8—psoriasis	4.16e-05	0.000713	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—SOCS1—psoriasis	4.16e-05	0.000713	CbGpPWpGaD
Buprenorphine—Headache—Betamethasone—psoriasis	4.15e-05	0.000191	CcSEcCtD
Buprenorphine—Headache—Dexamethasone—psoriasis	4.15e-05	0.000191	CcSEcCtD
Buprenorphine—Asthenia—Prednisone—psoriasis	4.14e-05	0.00019	CcSEcCtD
Buprenorphine—Pain—Methotrexate—psoriasis	4.12e-05	0.000189	CcSEcCtD
Buprenorphine—Pruritus—Prednisone—psoriasis	4.08e-05	0.000188	CcSEcCtD
Buprenorphine—OPRM1—Signaling by GPCR—CCL20—psoriasis	4.04e-05	0.000693	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TAGAP—psoriasis	3.99e-05	0.000683	CbGpPWpGaD
Buprenorphine—Feeling abnormal—Methotrexate—psoriasis	3.97e-05	0.000183	CcSEcCtD
Buprenorphine—OPRL1—Signaling by GPCR—TYK2—psoriasis	3.96e-05	0.000679	CbGpPWpGaD
Buprenorphine—Diarrhoea—Prednisone—psoriasis	3.95e-05	0.000181	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Methotrexate—psoriasis	3.94e-05	0.000181	CcSEcCtD
Buprenorphine—ABCB1—Allograft Rejection—CXCL8—psoriasis	3.94e-05	0.000676	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.94e-05	0.000675	CbGpPWpGaD
Buprenorphine—Nausea—Betamethasone—psoriasis	3.94e-05	0.000181	CcSEcCtD
Buprenorphine—Nausea—Dexamethasone—psoriasis	3.94e-05	0.000181	CcSEcCtD
Buprenorphine—CYP2A6—Metabolism—CYP2S1—psoriasis	3.92e-05	0.000672	CbGpPWpGaD
Buprenorphine—Urticaria—Methotrexate—psoriasis	3.83e-05	0.000176	CcSEcCtD
Buprenorphine—Dizziness—Prednisone—psoriasis	3.82e-05	0.000175	CcSEcCtD
Buprenorphine—Body temperature increased—Methotrexate—psoriasis	3.81e-05	0.000175	CcSEcCtD
Buprenorphine—Abdominal pain—Methotrexate—psoriasis	3.81e-05	0.000175	CcSEcCtD
Buprenorphine—OPRL1—GPCR downstream signaling—CXCL8—psoriasis	3.8e-05	0.000651	CbGpPWpGaD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.77e-05	0.000646	CbGpPWpGaD
Buprenorphine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	3.7e-05	0.000634	CbGpPWpGaD
Buprenorphine—Vomiting—Prednisone—psoriasis	3.67e-05	0.000169	CcSEcCtD
Buprenorphine—Rash—Prednisone—psoriasis	3.64e-05	0.000167	CcSEcCtD
Buprenorphine—CYP3A5—Metabolism—NDUFA5—psoriasis	3.63e-05	0.000623	CbGpPWpGaD
Buprenorphine—Dermatitis—Prednisone—psoriasis	3.63e-05	0.000167	CcSEcCtD
Buprenorphine—Headache—Prednisone—psoriasis	3.61e-05	0.000166	CcSEcCtD
Buprenorphine—Hypersensitivity—Methotrexate—psoriasis	3.55e-05	0.000163	CcSEcCtD
Buprenorphine—OPRM1—G alpha (i) signalling events—CXCL8—psoriasis	3.51e-05	0.000602	CbGpPWpGaD
Buprenorphine—Asthenia—Methotrexate—psoriasis	3.46e-05	0.000159	CcSEcCtD
Buprenorphine—OPRL1—Signaling by GPCR—CXCL8—psoriasis	3.45e-05	0.000592	CbGpPWpGaD
Buprenorphine—Nausea—Prednisone—psoriasis	3.43e-05	0.000157	CcSEcCtD
Buprenorphine—Pruritus—Methotrexate—psoriasis	3.41e-05	0.000157	CcSEcCtD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	3.38e-05	0.000579	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	3.38e-05	0.000579	CbGpPWpGaD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.3e-05	0.000567	CbGpPWpGaD
Buprenorphine—Diarrhoea—Methotrexate—psoriasis	3.3e-05	0.000152	CcSEcCtD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.25e-05	0.000557	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCL20—psoriasis	3.22e-05	0.000552	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—VEGFA—psoriasis	3.2e-05	0.000549	CbGpPWpGaD
Buprenorphine—Dizziness—Methotrexate—psoriasis	3.19e-05	0.000146	CcSEcCtD
Buprenorphine—CYP2C8—Metabolism—NDUFA5—psoriasis	3.15e-05	0.00054	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—CARM1—psoriasis	3.14e-05	0.000539	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CYP2S1—psoriasis	3.09e-05	0.00053	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—LEP—psoriasis	3.07e-05	0.000526	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—APOE—psoriasis	3.07e-05	0.000526	CbGpPWpGaD
Buprenorphine—Vomiting—Methotrexate—psoriasis	3.07e-05	0.000141	CcSEcCtD
Buprenorphine—Rash—Methotrexate—psoriasis	3.04e-05	0.00014	CcSEcCtD
Buprenorphine—Dermatitis—Methotrexate—psoriasis	3.04e-05	0.00014	CcSEcCtD
Buprenorphine—Headache—Methotrexate—psoriasis	3.02e-05	0.000139	CcSEcCtD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.94e-05	0.000503	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—CXCL8—psoriasis	2.87e-05	0.000492	CbGpPWpGaD
Buprenorphine—Nausea—Methotrexate—psoriasis	2.86e-05	0.000132	CcSEcCtD
Buprenorphine—OPRL1—Signaling Pathways—NFKBIA—psoriasis	2.86e-05	0.00049	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCL20—psoriasis	2.82e-05	0.000484	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—NDUFA5—psoriasis	2.81e-05	0.000482	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.79e-05	0.000479	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—TNF—psoriasis	2.74e-05	0.00047	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—NDUFA5—psoriasis	2.74e-05	0.00047	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.73e-05	0.000468	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CYP2S1—psoriasis	2.68e-05	0.000459	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.66e-05	0.000457	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.62e-05	0.000449	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—NDUFA5—psoriasis	2.58e-05	0.000443	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—NDUFA5—psoriasis	2.56e-05	0.000439	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.55e-05	0.000437	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—CXCL8—psoriasis	2.52e-05	0.000431	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—CARM1—psoriasis	2.48e-05	0.000426	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.43e-05	0.000417	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CYP2S1—psoriasis	2.39e-05	0.00041	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.39e-05	0.00041	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCL20—psoriasis	2.39e-05	0.000409	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—TYK2—psoriasis	2.34e-05	0.000401	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CYP2S1—psoriasis	2.33e-05	0.0004	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.32e-05	0.000398	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CYP2S1—psoriasis	2.2e-05	0.000377	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—NDUFA5—psoriasis	2.19e-05	0.000375	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CYP2S1—psoriasis	2.18e-05	0.000374	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—CXCL8—psoriasis	2.13e-05	0.000365	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—CARM1—psoriasis	2.11e-05	0.000361	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—CARM1—psoriasis	2.09e-05	0.000358	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.04e-05	0.00035	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CXCL8—psoriasis	2.04e-05	0.000349	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—IL6—psoriasis	1.94e-05	0.000332	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—CAT—psoriasis	1.93e-05	0.000331	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—CARM1—psoriasis	1.91e-05	0.000328	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—JUN—psoriasis	1.89e-05	0.000325	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP2S1—psoriasis	1.86e-05	0.000319	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—NFKB1—psoriasis	1.82e-05	0.000313	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.81e-05	0.00031	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—SOCS1—psoriasis	1.77e-05	0.000304	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.74e-05	0.000298	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—TYK2—psoriasis	1.69e-05	0.00029	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NDUFA5—psoriasis	1.69e-05	0.00029	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—VEGFA—psoriasis	1.66e-05	0.000284	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—STAT3—psoriasis	1.64e-05	0.000281	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—CXCL8—psoriasis	1.62e-05	0.000278	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.58e-05	0.000271	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SOCS1—psoriasis	1.56e-05	0.000267	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—CAT—psoriasis	1.53e-05	0.000262	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CARM1—psoriasis	1.51e-05	0.000259	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—APOE—psoriasis	1.5e-05	0.000257	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—TYK2—psoriasis	1.48e-05	0.000254	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—CXCL8—psoriasis	1.47e-05	0.000253	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP2S1—psoriasis	1.44e-05	0.000246	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—CXCL8—psoriasis	1.42e-05	0.000244	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.4e-05	0.000241	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.35e-05	0.000232	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SOCS1—psoriasis	1.31e-05	0.000225	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—APOE—psoriasis	1.31e-05	0.000224	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—LEP—psoriasis	1.31e-05	0.000224	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PPARG—psoriasis	1.31e-05	0.000224	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CARM1—psoriasis	1.31e-05	0.000224	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—CAT—psoriasis	1.3e-05	0.000222	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—CXCL8—psoriasis	1.29e-05	0.000221	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—CAT—psoriasis	1.28e-05	0.00022	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—TYK2—psoriasis	1.25e-05	0.000215	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.25e-05	0.000215	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—TP53—psoriasis	1.25e-05	0.000214	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.22e-05	0.00021	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NFKBIA—psoriasis	1.22e-05	0.000209	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—CXCL8—psoriasis	1.2e-05	0.000206	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.19e-05	0.000205	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—APOE—psoriasis	1.19e-05	0.000203	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—CAT—psoriasis	1.18e-05	0.000202	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CARM1—psoriasis	1.17e-05	0.0002	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—LEP—psoriasis	1.15e-05	0.000197	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—APOE—psoriasis	1.15e-05	0.000197	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—IL6—psoriasis	1.14e-05	0.000196	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.14e-05	0.000196	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CARM1—psoriasis	1.14e-05	0.000195	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CXCL8—psoriasis	1.09e-05	0.000187	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.09e-05	0.000187	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CARM1—psoriasis	1.07e-05	0.000184	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NFKBIA—psoriasis	1.07e-05	0.000183	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CARM1—psoriasis	1.06e-05	0.000182	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PPARG—psoriasis	1.03e-05	0.000177	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—APOE—psoriasis	1.01e-05	0.000173	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TYK2—psoriasis	9.99e-06	0.000171	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—APOE—psoriasis	9.98e-06	0.000171	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.95e-06	0.000171	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.76e-06	0.000167	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—APOE—psoriasis	9.7e-06	0.000166	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—LEP—psoriasis	9.7e-06	0.000166	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CAT—psoriasis	9.28e-06	0.000159	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—APOE—psoriasis	9.15e-06	0.000157	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CARM1—psoriasis	9.09e-06	0.000156	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NFKBIA—psoriasis	9.04e-06	0.000155	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PPARG—psoriasis	8.77e-06	0.00015	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TYK2—psoriasis	8.76e-06	0.00015	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CXCL8—psoriasis	8.7e-06	0.000149	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PPARG—psoriasis	8.69e-06	0.000149	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.5e-06	0.000146	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—IL6—psoriasis	8.27e-06	0.000142	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—JUN—psoriasis	8.09e-06	0.000139	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CAT—psoriasis	8.04e-06	0.000138	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PPARG—psoriasis	7.97e-06	0.000137	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NFKB1—psoriasis	7.79e-06	0.000133	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CXCL8—psoriasis	7.63e-06	0.000131	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TYK2—psoriasis	7.4e-06	0.000127	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—IL6—psoriasis	7.25e-06	0.000124	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—APOE—psoriasis	7.21e-06	0.000124	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CAT—psoriasis	7.18e-06	0.000123	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—JUN—psoriasis	7.09e-06	0.000122	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—VEGFA—psoriasis	7.07e-06	0.000121	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CARM1—psoriasis	7.02e-06	0.00012	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CAT—psoriasis	7.01e-06	0.00012	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—STAT3—psoriasis	7e-06	0.00012	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NFKB1—psoriasis	6.83e-06	0.000117	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CAT—psoriasis	6.6e-06	0.000113	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CAT—psoriasis	6.54e-06	0.000112	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CXCL8—psoriasis	6.45e-06	0.000111	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PPARG—psoriasis	6.28e-06	0.000108	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—APOE—psoriasis	6.25e-06	0.000107	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VEGFA—psoriasis	6.2e-06	0.000106	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—STAT3—psoriasis	6.13e-06	0.000105	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—IL6—psoriasis	6.13e-06	0.000105	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—JUN—psoriasis	5.99e-06	0.000103	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NFKB1—psoriasis	5.77e-06	9.89e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CAT—psoriasis	5.59e-06	9.59e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—APOE—psoriasis	5.58e-06	9.56e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—APOE—psoriasis	5.44e-06	9.33e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PPARG—psoriasis	5.44e-06	9.33e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TP53—psoriasis	5.34e-06	9.15e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VEGFA—psoriasis	5.24e-06	8.98e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—STAT3—psoriasis	5.18e-06	8.89e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—APOE—psoriasis	5.13e-06	8.79e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—APOE—psoriasis	5.08e-06	8.72e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL6—psoriasis	4.89e-06	8.38e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PPARG—psoriasis	4.86e-06	8.33e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PPARG—psoriasis	4.74e-06	8.13e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TP53—psoriasis	4.68e-06	8.03e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PPARG—psoriasis	4.47e-06	7.66e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PPARG—psoriasis	4.43e-06	7.59e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—APOE—psoriasis	4.35e-06	7.45e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CAT—psoriasis	4.32e-06	7.4e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL6—psoriasis	4.29e-06	7.35e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TP53—psoriasis	3.96e-06	6.78e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PPARG—psoriasis	3.78e-06	6.49e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL6—psoriasis	3.62e-06	6.21e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—APOE—psoriasis	3.35e-06	5.75e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PPARG—psoriasis	2.92e-06	5.01e-05	CbGpPWpGaD
